Xenetic Biosciences (NASDAQ:XBIO) Given Neutral Rating at HC Wainwright

HC Wainwright reiterated their neutral rating on shares of Xenetic Biosciences (NASDAQ:XBIO) in a report released on Friday,Benzinga reports.

Xenetic Biosciences Trading Up 2.5 %

Shares of NASDAQ XBIO opened at $4.11 on Friday. The business has a fifty day simple moving average of $3.91 and a 200 day simple moving average of $3.92. The firm has a market capitalization of $6.33 million, a price-to-earnings ratio of -1.54 and a beta of 2.25. Xenetic Biosciences has a one year low of $2.78 and a one year high of $5.20.

Xenetic Biosciences (NASDAQ:XBIO) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.14). The firm had revenue of $0.61 million for the quarter, compared to the consensus estimate of $0.75 million. Xenetic Biosciences had a negative net margin of 161.63% and a negative return on equity of 49.51%. On average, research analysts anticipate that Xenetic Biosciences will post -1.01 earnings per share for the current fiscal year.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.